Please assess the completion status of the following clinical trial:

Trial Title: Nicotinamide Riboside in Systolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 and older with systolic heart failure \[left ventricular ejection fraction (LVEF) by standard 2D echocardiography or radionuclide ventriculography of ≤40%\] deemed, in the clinical opinion of their treating cardiologist to be non-ischemic or ischemic in origin.~* Clinically stable (no cardiac procedures or hospitalizations for hospitalizations for cardiac causes, including HF, ischemia or arrhythmia) within the previous 3 months~* Ability to undergo study procedures, including scheduled visits, blood draws and six-minute walk test (6MWT)~* Willingness/ability to provide informed consent~Exclusion Criteria:~* Heart failure with preserved ejection fraction (LVEF greater than 40%)~* Heart failure due, in the opinion of their treating cardiologist, to etiologies other than non-ischemic or ischemic. Examples of exclusionary heart failure etiologies include primary valvular disease, or infiltrative or inflammatory cardiomyopathies.~* Cardiac surgery, percutaneous coronary intervention (PCI) or cardiac device implantation within the previous 3 months~* Hospitalizations for cardiovascular causes, including heart failure, chest pain, stroke, transient ischemic attack or arrhythmias within the previous 3 months~* Inability to perform Study visits or procedures (e.g., physical inability to perform 6MWT)~* Unwillingness/inability to provide informed consent~* ALT greater than 3 times the upper limit of normal, hepatic insufficiency or active liver disease~* Recent history of acute gout~* Chronic renal insufficiency with creatinine ≥2.5mg/dL~* Pregnant (or likely to become pregnant) women~* Significant co-morbidity likely to cause death in the 6 month follow-up period~* Significant active history of substance abuse within the previous 5 years~* Current participation in another long-term clinical trial~* History of intolerance to NR precursor compounds, including niacin or nicotinamide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nicotinamide Riboside (Type: EXPERIMENTAL): Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).